Non-vitamin K antagonist direct oral anticoagulants (NOACs) have largely replaced vitamin K antagonists for stroke prevention in atrial fibrillation in most clinical settings.
NOACs have largely replaced vitamin K antagonists for stroke prevention in most clinical settings of atrial fibrillation.
Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with substantial increases in the risk of stroke and systemic thromboembolism. With the successful introduction of the first non-vitamin K antagonist direct oral anticoagulant (NOAC) in 2009, the role of vitamin K antagonists has been replaced in most clinical settings except in a few conditions when NOACs are contraindicated. Data for the use of NOACs in different clinical scenarios have been accumulating in the recent decade, and a more sophisticated strategy for atrial fibrillation patients is now warranted.
Chiang et al. (Mon,) conducted a review in Atrial fibrillation. NOACs vs. Vitamin K antagonists was evaluated. Non-vitamin K antagonist direct oral anticoagulants (NOACs) have largely replaced vitamin K antagonists for stroke prevention in atrial fibrillation in most clinical settings.